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Abstract
Background
The genetic architecture of coronary artery disease has not been fully elucidated, especially
in Asian countries. Moyamoya disease is a progressive cerebrovascular disease that is
reported to be complicated by coronary artery disease. Because most Japanese patients
with moyamoya disease carry the p.R4810K variant of the ring finger 213 gene (RNF213),
this may also be a risk factor for coronary artery disease; however, this possibility has never
been tested.
Methods and results
We genotyped the RNF213 p.R4810K variant in 956 coronary artery disease patients and
716 controls and tested the association between p.R4810K and coronary artery disease.
We also validated the association in an independent population of 311 coronary artery dis-
ease patients and 494 controls. In the replication study, the p.R4810K genotypes were
imputed from genome-wide genotyping data based on the 1000 Genomes Project. We used
multivariate logistic regression analyses to adjust for well-known risk factors such as dyslipi-
demia and smoking habits. In the primary study population, the frequency of the minor vari-
ant allele was significantly higher in patients with coronary artery disease than in controls
(2.04% vs. 0.98%), with an odds ratio of 2.11 (p = 0.017). Under a dominant model, after
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adjustment for risk factors, the association remained significant, with an odds ratio of 2.90
(95% confidence interval: 1.37–6.61; p = 0.005). In the replication study, the association
was significant after adjustment for age and sex (odds ratio = 4.99; 95% confidence interval:
1.16–21.53; p = 0.031), although it did not reach statistical significance when further
adjusted for risk factors (odds ratio = 3.82; 95% confidence interval: 0.87–16.77; p = 0.076).
Conclusions
The RNF213 p.R4810K variant appears to be significantly associated with coronary artery
disease in the Japanese population.
Introduction
Together with the Westernization of lifestyles, the number of patients with coronary artery dis-
ease (CAD) has increased in Japan and become a major public health concern.[1] Although
the mortality rate of CAD in Japan is one-third to one-fifth of that in the United States,[2–5]
cardiovascular disease has become the second-leading cause of death.[6] This trend is also
seen in other Asian countries.[7–9] CAD is considered a multifactorial disease resulting from
interactions between genetic and environmental factors.[10] Extensive genetic studies have
identified more than 50 loci associated with CAD,[11] but the genetic architecture of CAD
remains to be fully elucidated, especially in Asian populations.
Moyamoya disease (MMD) is a rare chronic progressive cerebrovascular disease characterized
by stenosis/occlusion of the arteries around the circle of Willis with prominent arterial collateral
circulation, which resembles a puff of smoke that is called moyamoya in Japanese.[12] Stenosis of
the extracranial arteries including coronary and renal arteries has been documented in patients
with MMD.[13] Co-incidence with CAD was observed in 4.6% of patients with MMD,[14] and
familial co-occurrence of early-onset CAD with MMD has recently been reported.[15] These find-
ings suggest the existence of a risk factor common to MMD and CAD. Recently, the p.R4810K
(c.14429G>A: rs112735431) variant of the ring finger 213 gene (RNF213) was identified as an
MMD susceptibility variant by two independent groups in Japan.[16,17] Furthermore, one of
these groups cloned the entire RNF213 cDNA, characterized the functions of RNF213 as ATPase
and E3 ligase, and showed a founder effect of this variant among East Asian patients. They also
described the involvement of other variants in European patients with MMD.[17]
In Japan and South Korea, ~80% of MMD patients and 0.5%–3.1% of the general popula-
tion carry the RNF213 p.R4810K variant,[16–21] so it is possible that this variant may also be
associated with CAD in the general population. Therefore, in the present study, we tested for
an association of the RNF213 p.R4810K variant with CAD in the Japanese population.
Materials and methods
Ethics statement
This study was conducted in accordance with Declaration of Helsinki standards, and approved
by the ethics committee of Kyoto University (approval no. G342), Aichi Gakuin University
(approval no. 64), Mie University (approval no. 1207), Nagoya University (approval no. 102–3,
103–2), and Kyushu University (approval no. 205). Written informed consent was obtained
from all participants before participation.
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Study populations
We conducted a case–control study to test the association of the p.R4810K variant in RNF213
with CAD in the Japanese population. We first tested the association in the primary study pop-
ulation consisting of 956 Japanese patients with CAD and 716 controls, and then repeated it
in the replication study population consisting of 311 Japanese patients with CAD and 494
controls.
In the primary study population, among the 1039 patients who were admitted to Kyoto
University Hospital for the evaluation of CAD by coronary angiography between April 2009
and December 2014, we excluded 20 patients of non-Japanese ethnicity and 63 patients whose
blood serum was unavailable; 956 Japanese patients with CAD were ultimately selected. The
diagnosis of CAD was defined as the occurrence of myocardial infarction or angina pectoris
verified by coronary angiography, electrocardiogram, and echocardiogram. The diagnosis of
myocardial infarction was based on typical electrocardiographic changes and increased serum
activities of enzymes including creatine kinase, aspartate aminotransferase, and lactate dehy-
drogenase; it was confirmed by the presence of a wall motion abnormality on left ventriculo-
graphy and attendant stenosis in any of the major coronary arteries. Control subjects consisted
of a cohort recruited in Nyukawa, a village in Gifu Prefecture, Japan, between 2004 and 2006.
Among 732 potential controls, 716 individuals who did not have an abnormal Q wave, coro-
nary T wave, or ST elevation by electrocardiogram, or a medical history of cardiac disease,
were included in the study.
In the replication study, a total of 551 case subjects and 500 control subjects were previously
genotyped using an Illumina Human660W-Quad BeadChip (Illumina, San Diego, USA).
[22,23] The 551 patients with CAD were individuals previously recruited through participating
hospitals in Japan.[24] Some of the cases were siblings with CAD, and their data had previ-
ously been used in a genome-wide linkage study for CAD.[22] The 500 control subjects were
randomly selected from participants of the ongoing Kita-Nagoya Genomic Epidemiology
study (ClinicalTrials.gov identifier, NCT00262691).[25–27] Data from the control subjects
have previously been used in genome-wide association studies.[23,28]
Clinical data regarding obesity, hypertension, dyslipidemia, diabetes mellitus, and number
of affected vessels were collected at first admission for patients with CAD and at the latest
check-up for control subjects. Obesity was defined as a body mass index27 kg/m2.[29]
Hypertension was defined as a systolic blood pressure of140 mmHg or a diastolic blood
pressure of90 mmHg, according to the Japanese Society of Hypertension Guidelines for the
Management of Hypertension.[30] Dyslipidemia was defined as a high-density lipoprotein
cholesterol (HDL-C) level<40 mg/dl, a low-density lipoprotein cholesterol (LDL-C) level
140 mg/dl, or a triglyceride level150 mg/dl, according to the Japan Atherosclerosis Society
guidelines.[31] Diabetes was defined as a fasting plasma glucose level126 mg/dl, a 2-h
plasma glucose200 mg/dl during an oral glucose tolerance test or a casual plasma glucose
level200 mg/dl, together with hemoglobin A1c (HbA1c)6.5%, based on the guidelines of
the Japan Diabetes Society.[32] The HbA1c level was estimated as the National Glycohemoglo-
bin Standardization Program equivalent value, calculated using the following formula: HbA1c
(%) = HbA1c (Japan Diabetes Society; %) + 0.4.[32] Individuals were also recorded as having
hypertension, dyslipidemia, or diabetes if they had been on medication for any of these condi-
tions. The number of affected vessels showing stenosis50% from the main coronary artery
(right coronary artery, left anterior descending coronary artery, or circumflex coronary artery)
was evaluated by coronary angiography.
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Genotyping and imputing the RNF213 p.R4810K variant
Genomic DNA was obtained from peripheral blood samples using a DNA Blood Mini Kit
(Qiagen, Hilden, Germany). For the primary study population, genotyping of RNF213 p.
R4810K was performed using TaqMan single nucleotide polymorphism (SNP) Genotyping
Assays (Applied Biosystems, Foster City, CA), as previously described.[17] Because it was diffi-
cult to evaluate the TaqMan results in 26 subjects, we directly sequenced the variant-contain-
ing exon 60 of RNF213 (NM_020954.3) in these individuals using primers described
previously.[17]
In the replication study, we imputed the p.R4810K genotypes using genome-wide genotyp-
ing data from 1051 subjects who were genotyped using a Human660W-Quad BeadChip.
[22,23] The case subjects included CAD sib-pairs. To detect sib-pair samples or other relatives
among the samples, we determined whether the estimated genome-wide identity-by-descent
(IBD) proportion of alleles shared was >0.1875. We estimated IBD sharing using the PLINK
option ‘—genome’ on a linkage disequilibrium (LD)-pruned set of SNPs, which was obtained
by removing large-scale high-LD regions or SNPs with a genotype call rate<0.98, or a minor
allele frequency (MAF) <0.01, or Hardy–Weinberg equilibrium (HWE) (p<1×10−6). LD
pruning was performed using the PLINK option ‘—indep-pairwise 50 5 0.2’. Based on the IBD
sharing, any family relatedness was identified and excluded from further analyses. After quality
control, 225 subjects were excluded. An additional 21 subjects were excluded because of miss-
ing clinical information. Therefore, 311 case subjects and 494 control subjects remained for
further analysis. We excluded any SNPs with a genotype call rate<0.98, a MAF <0.01, an
HWE p<1×10−6, or a departure from the allele frequency computed from the 1000 Genomes
Phase 3 EAS samples. The remaining 12,364 SNPs on chromosome 17 were used for the impu-
tation procedure. We imputed genotypes using SHAPEIT2 [33] and minimac3 (genome.sph.
umich.edu/wiki/Minimac3) with data from the 1000 Genomes Phase 3 all ancestries as a refer-
ence panel. The imputed data for the RNF213 p.R4810K variant passed the imputation quality
criteria (Rsq <0.3).
Statistical analysis
Continuous variables were presented as means ± standard deviation and compared using Stu-
dent’s t-test. Categorical variables were presented as proportions and compared with the chi-
squared test or Fisher’s exact test where appropriate. HWE was assessed using chi-squared tests.
We performed multivariate logistic regression analyses to evaluate the associations between p.
R4810K and CAD, with adjustment for CAD risk factors including age, sex, obesity, hypertension,
dyslipidemia, diabetes, and smoking. We also assessed the association of imputed genotypes of
the RNF213 p.R4810K variant with CAD using a logistic regression analysis; the dependent vari-
able was CAD label (case = 1, control = 0), and the independent variables included the imputed
allele dosage of the variant and covariates. The covariates comprised CAD risk factors. A p value
< 0.05 was considered statistically significant and a p value of<0.1 and0.05 was considered
marginally significant. All data analysis was carried out using JMP pro version 11.2.0 (SAS Insti-
tute, Cary, NC), the R project (version 3.3.0, www.r-project.org), and EPACTS (version 3.2.6,
genome.sph.umich.edu/wiki/EPACTS).
Results
The demographic and clinical characteristics of the primary study subjects are shown in
Table 1. Of all the subjects, 695 cases and 304 controls were male, and 261 cases and 412 con-
trols were female, indicating the male predominance of CAD. The controls were younger than
the cases. As expected, the frequencies of conventional CAD risk factors including obesity,
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hypertension, dyslipidemia, diabetes, and smoking were significantly higher in cases than in
controls. Although systolic blood pressure, blood glucose levels, and triglyceride levels were
higher in cases than controls, total cholesterol, HDL-C, and LDL-C levels were lower in cases
than controls. The lower LDL-C and total cholesterol levels in cases likely reflect the effect of
lipid-lowering medications.
Significant association of the RNF213 p.R4810K variant with CAD
The allele frequencies of the p.R4810K variant in CAD patients and controls are summarized
in Table 2. The variant was in HWE both in patients with CAD (p = 0.055) and in controls
(p = 0.062). The risk allele frequency was 2.04% in patients with CAD and 0.98% in controls,
and there was a significant allelic association of the p.R4810K variant with CAD (p = 0.017).
Among the genetic models, the additive and dominant models showed a significant associa-
tion. Under the dominant model, which is the observed inheritance pattern of MMD,[34,35]
the frequency of the risk genotypes (GA+AA) was significantly higher in patients with CAD
than in controls (3.87% vs. 1.82%), with an odds ratio (OR) of 2.18 (p = 0.019; 95% confidence
interval [CI], 1.15–4.13). As shown in Table 3, the association of the p.R4810K variant with
CAD remained significant (OR = 2.90; 95% CI, 1.37–6.61; p = 0.005) by multivariate logistic
regression analysis, after adjustment for the major confounding variables including age, sex,
obesity, hypertension, dyslipidemia, diabetes, and smoking. The association was more promi-
nent in men (OR = 4.36; 95% CI, 1.61–14.7; p = 0.003) than in women (OR = 1.39; 95% CI,
0.35–5.71; p = 0.644), although the interaction with sex was not statistically significant
(Table 3; p = 0.415). Because a previous study reported that p.R4810K variant was associated
with higher systolic blood pressure but not with hypertension [36], we performed multivariate
analysis by replacing history of hypertension with systolic blood pressure. The association of
the p.R4810K with CAD remained significant (OR = 2.63; 95% CI, 1.32–5.53; p = 0.005).
Table 2. Association of the RNF213 p.R4810K variant (c.14429G>A) with CAD in the primary study.
Total (n = 1672) Men (n = 999) Women (n = 673)
RNF213
p.R4810K
CAD,
n (%)
Control,
n (%)
p value OR (95% CI) CAD, n (%) Control, n (%) p value OR (95% CI) CAD, n (%) Control, n (%) p value OR
(95% CI)
Allele G 1873
(98.0)
1418
(99.0)
1359 (97.8) 602 (99.0) 514 (98.5) 816 (99.0)
A 39
(2.0)
14 (1.0) 0.017 2.11 (1.14–
3.90)
31 (2.2) 6 (1.0) 0.070 2.29 (0.95–
5.51)
8 (1.5) 8 (1.0) 0.440 1.59
(0.59–
4.26)
Additive
model
GG 919
(96.1)
703
(98.2)
666 (95.8) 299 (98.4) 253 (96.9) 404 (98.1)
GA 35
(3.7)
12 (1.7) 0.017 1.99 (1.13–
3.76)
27 (3.9) 4 (1.3) 0.184 2.04 (0.74–
8.40)
8 (3.1) 8 (1.9) 0.357 1.60
(0.58–
4.39)
AA 2
(0.2)
1 (0.1) 3.97 (1.27–
14.12)
2 (0.3) 1 (0.3) 4.16 (0.55–
70.61)
0 (0) 0 (0) –
Dominant
model
GG 919
(96.1)
703
(98.2)
666 (95.8) 299 (98.4) 253 (96.9) 404 (98.1)
GA+AA 37
(3.9)
13 (1.8) 0.019 2.18 (1.15–
4.13)
29 (4.2) 5 (1.6) 0.056 2.60 (1.00–
6.79)
8 (3.1) 8 (1.9) 0.437 1.60
(0.59–
4.31)
Recessive
model
AA 2
(0.2)
1 (0.1) 2 (0.3) 1 (0.3) 0 (0) 0 (0)
GG+GA 954
(99.8)
715
(99.9)
1 1.50 (0.14–
16.56)
693 (99.7) 303 (99.7) 1 0.87 (0.08–
9.68)
261 (100) 412 (100) 1 –
Abbreviations: CAD, coronary artery disease; CI, confidence interval; OR, odds ratio.
https://doi.org/10.1371/journal.pone.0175649.t002
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To validate the association of p.R4810K with CAD, we conducted a replication study in an
independent Japanese population. The detailed characteristics of the study population are
shown in Table 4. The cases were younger than the controls. The frequencies of conventional
CAD risk factors, except hypertension, were significantly higher in cases than in controls.
Table 5 shows the results of univariate and multivariate logistic regression analysis. Although
the association of p.R4810K with CAD did not reach statistical significance in the unadjusted
model (OR = 3.31; 95% CI, 0.83–13.17; p = 0.089), the association was significant after adjust-
ment for age and sex (OR = 4.99; 95% CI, 1.16–21.53; p = 0.031) and it was marginally signifi-
cant after adjustment for age, sex, obesity, hypertension, diabetes, and dyslipidemia
(OR = 3.82; 95% CI, 0.87–16.77; p = 0.076).
Clinical characteristics of CAD patients with and without RNF213 p.
R4810K
We next compared the clinical characteristics between CAD patients with and without the p.
R4810K variant in the primary population (Table 6). The number of affected vessels was not
Table 3. Multivariate analysis of the risk of coronary artery disease in the primary study.
Variables Total Men Women
OR 95%CI p value OR 95%CI p value OR 95%CI p value p for interaction with
sex*
RNF213 p.R4810K (GG vs GA
+AA)
2.90 1.37–6.61 0.005 4.36 1.61–
14.70
0.003 1.39 0.35–5.71 0.644 0.415
Age 1.09 1.08–1.11 <0.001 1.07 1.06–1.09 <0.001 1.14 1.11–1.17 <0.001 <0.001
Sex 1.43 1.04–1.96 0.026 NA NA NA NA NA NA NA
Obesity 1.49 0.98–2.31 0.064 1.80 1.05–3.17 0.033 1.03 0.48–2.18 0.941 0.182
Hypertension 2.15 1.63–2.84 <0.001 2.29 1.60–3.27 <0.001 1.82 1.15–2.89 0.010 0.767
Diabetes mellitus 8.24 5.67–
12.27
<0.001 7.56 4.71–
12.71
<0.001 10.68 5.77–
20.87
<0.001 0.619
Dyslipidemia 1.81 1.37–2.39 <0.001 1.69 1.19–2.40 0.003 1.84 1.15–2.99 0.011 0.664
Smoking 4.12 2.99–5.72 <0.001 3.08 2.18–4.37 <0.001 25.91 9.32–
85.71
<0.001 <0.001
*: the p value was adjusted for age. Abbreviations: CI, confidence interval; OR, odds ratio; NA, not applicable.
https://doi.org/10.1371/journal.pone.0175649.t003
Table 4. Demographic and clinical characteristics of the replication study participants.
Variable CAD Control OR (95%CI) p value
Number, n 311 494
Age, Years (SD) 62.8 (9.4) 69.5 (3.8) < 0.001
Male sex, n (%) 259 (83.3) 388 (78.5) 1.36 (0.93–2.01) 0.102
Obesity, n (%) 51 (16.4) 41 (8.3) 2.17 (1.37–3.45) < 0.001
Hypertension, n (%) 181 (58.2) 296 (59.9) 0.93 (0.69–1.26) 0.659
Dyslipidemia, n (%) 199 (64.0) 217 (43.9) 2.27 (1.68–3.07) < 0.001
Diabetes mellitus, n (%) 118 (37.9) 69 (14.0) 3.76 (2.64–5.39) < 0.001
Smoking habit, n (%) 206 (66.2) 257 (52.0) 1.81 (1.33–2.46) < 0.001
BMI (kg/m2), mean (SD) 24.4 (3.2) 23.2 (2.7) < 0.001
The differences in clinical characteristics between patients with CAD and controls were evaluated.
Data are presented as means ± SD or n (%). Continuous variables are expressed as means ± SD. Categorical variables are expressed as percentages.
Abbreviations: BMI, body mass index; CAD; coronary artery disease; CI, confidence interval; OR, odds ratio.
https://doi.org/10.1371/journal.pone.0175649.t004
RNF213 p.R4810K confers risk of coronary artery disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0175649 April 17, 2017 7 / 14
significantly different between the two groups. There were also no significant differences for
any risk variables between the GG and GA+AA genotypes except for diabetes, which was sig-
nificantly lower in GA+AA carriers (18.9%) than in GG carriers (40.9%: p = 0.0093). We tested
the possibility that the genotype effect may be confounded by diabetes, and investigated ORs
in non-diabetes cases (407 men and 166 women) and non-diabetes controls (283 men and 394
women). The ORs did not change by more than 20% except for obesity and smoking in
females (Table 7). This discounts the possibility of a confounding effect of the p.R4810K
Table 5. Univariate and multivariate logistic regression analysis of the replication study.
MAF Univariate Analysis Multivariate Analysis
Model A * Model B †
CAD Control OR 95%CI p value OR 95%CI p value OR 95%CI p value
Total 0.013 0.0058 3.31 0.83–13.17 0.089 3.82 0.87–16.77 0.076 4.99 1.16–21.53 0.031
Men 0.012 0.0062 2.82 0.64–12.51 0.171 3.21 0.65–15.81 0.152 3.66 0.78–17.06 0.099
Women 0.014 0.0044 7.68 0.21–283.8 0.268 9.88 0.15–664.4 0.286 50.44 1.04–2453.4 0.048
* Adjusted for age, sex, obesity, hypertension, diabetes and dyslipidemia.
† Adjusted for age and sex.
Abbreviations: CAD, coronary artery disease; CI, confidence interval; MAF, minor allele frequency; OR, odds ratio.
https://doi.org/10.1371/journal.pone.0175649.t005
Table 6. Clinical characteristics of the primary study population according to the RNF213 p.R4810K genotype (GG vs. GA+AA).
CAD (n = 956) Control (n = 716)
GG GA+AA p value GG GA+AA p value
Number, n 919 37 703 13
Age, years (SD) 71.0 (9.6) 69.1 (11.2) 0.249 58.8 (13.7) 58.6 (14.7) 0.961
Male sex, n (%) 666 (72.5) 29 (78.4) 0.418 299 (42.5) 5 (38.5) 0.768
Obesity, n (%) 127 (13.8) 6 (16.2) 0.686 55 (7.8) 2 (15.4) 0.370
Hypertension, n (%) 712 (77.5) 27 (72.3) 0.530 303 (43.1) 8 (61.5) 0.186
Dyslipidemia, n (%) 674 (73.0) 28 (75.7) 0.750 384 (54.6) 4 (30.8) 0.085
Diabetes mellitus, n (%) 376 (40.9) 7 (18.9) 0.0093 39 (5.6) 0 (0) 0.225
Smoking habit, n (%) 540 (58.8) 22 (59.5) 0.932 167 (23.8) 3 (23.1) 0.954
BMI (kg/m2), mean (SD) 23.5 (3.5) 24.1 (3.6) 0.377 22.9 (2.8) 23.6 (3.5) 0.366
SBP (mmHg), mean (SD) 132.3 (20.4) 136.0 (20.3) 0.273 126.3 (18.7) 133.4 (20.6) 0.177
DBP (mmHg), mean (SD) 73.0 (13.3) 75.0 (12.9) 0.377 73.4 (11.8) 74.2 (11.4) 0.813
TG (mg/dl), mean (SD) 136.0 (77.9) 154.9 (96.9) 0.153 101.4 (63.6) 81.2 (40.6) 0.255
TC (mg/dl), mean (SD) 174.4 (35.8) 172.5 (42.9) 0.760 202.6 (34.2) 201.7 (21.8) 0.926
HDL (mg/dl), mean (SD) 51.3 (14.8) 55.1 (16.3) 0.127 60.9 (14.9) 64.7 (10.3) 0.364
LDL (mg/dl), mean (SD) 98.2 (28.7) 92.7 (30.6) 0.256 121.7 (28.9) 120.7 (19.0) 0.901
FBS (mg/dl), mean (SD) 121.2 (44.9) 109.0 (53.1) 0.109 94.3 (14.3) 98.5 (10.2) 0.297
Number of affected vessels
1 365 (39.6) 12 (34.3) NA NA
2 262 (28.4) 11 (31.4) NA NA
3 294 (31.9) 12 (34.3) 0.852 NA NA
The differences in clinical characteristics according to the RNF213 p.R4810K genotype were evaluated in CAD patients and controls.
Data are presented as means ± SD or n (%). Continuous variables are expressed as means ± SD. Categorical variables are expressed as percentages.
Abbreviations: CAD, coronary artery disease; CI, confidence interval; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.
https://doi.org/10.1371/journal.pone.0175649.t006
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genotype on diabetes. Alternatively, it suggests that the risk of diabetes for CAD may be less
prominent in individuals with the GA+AA genotypes than in GG individuals. In other words,
the contribution of diabetes to CAD is smaller in the GA+AA population than in the wild-type
(GG) population.
Discussion
In this study, we revealed a significant association between the RNF213 p.R4810K variant and
CAD in the Japanese population. This variant is a major susceptibility factor for MMD.
[16,17,19,37–39] In the primary study population, the allele frequency of p.R4810K was 2.04%
in CAD patients and 0.98% in controls, and we observed a significant association of the p.
R4810K variant with CAD, with an OR of 2.11. Under the dominant model, the carrier fre-
quency was 3.87% in CAD patients and 1.82% in controls. Multivariate regression analysis
showed a significant association of the risk variant with CAD after adjustment for common
risk factors, with an OR of 2.90. Adjustment with systolic blood pressure, a variant previously
shown to be associated with p.R4810K, did not alter the results. These findings indicate that
the p.R4810K variant was an independent risk factor for CAD. To confirm this association, we
replicated the study in an independent population. In an age- and sex-adjusted model, the
association was confirmed to be significant, with an OR of 4.99. However, after adjustment for
CAD risk factors including age, sex, obesity, hypertension, dyslipidemia, diabetes, and smok-
ing, the association was only marginally significant. This could be because of insufficient statis-
tical power after selecting populations for quality control, so additional replication studies are
warranted to confirm these findings. The difference between men and women was not signifi-
cant. The association was more pronounced in men than in women in the primary study,
whereas the replication study showed the opposite result. The reason for this discrepancy was
not clear.
The association of a rare variant with CAD has rarely been reported to date. Do et al. per-
formed exome sequence analysis on patients with myocardial infarction and found that a set
of non-synonymous mutations in the low-density lipoprotein receptor gene, with a total MAF
Table 7. Multivariate analysis of the risk of coronary artery disease among the primary study population without a history of diabetes mellitus.
Variables Total Men Women
OR 95%CI p value % OR
change*
OR 95%CI p value % OR
change*
OR 95%CI p value % OR
change*
RNF213 p.
R4810K
2.74 1.23–
6.07
0.013 -5.5 4.29 1.43–
12.83
<0.001 -1.6 1.19 0.25–5.34 0.820 -14.4
(GG vs GA+AA)
Age 1.10 1.08–
1.11
<0.001 0.9 1.08 1.06–1.09 <0.001 0.9 1.15 1.12–1.19 <0.001 0.9
Sex 1.45 1.93–
2.05
0.032 1.4 NA NA NA NA NA NA NA NA
Obesity 1.77 1.10–
2.86
0.020 18.8 2.04 1.10–3.77 0.023 13.3 1.37 0.57–3.20 0.47 33.0
Hypertension 2.06 1.53–
2.79
<0.001 -4.2 2.35 1.59–3.46 <0.001 2.6 1.77 1.01–3.12 0.045 -2.7
Dyslipidemia 1.83 1.36–
2.47
<0.001 1.1 1.68 1.15–2.44 0.007 -0.6 1.94 1.16–3.31 0.012 5.4
Smoking 4.20 2.94–
5.96
<0.001 1.9 3.00 2.06–4.37 <0.001 -2.6 36.7 11.9–
139.8
<0.001 41.6
*: Compared with Table 3 and this table. Abbreviations: CI, confidence interval; OR, odds ratio.
https://doi.org/10.1371/journal.pone.0175649.t007
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of 1.3%, was associated with a 2.4-fold increased risk of myocardial infarction.[40] The muta-
tion burden of the apolipoprotein A-V gene was also shown to be associated with a 2.0-fold
increased risk of CAD, with a MAF of 0.46%.
When comparing the clinical characteristics of patients with GA+AA genotypes with those
with the GG genotype in the present study, the extent of CAD (the number of affected coro-
nary arteries) and the prevalence of comorbidities were comparable between groups, except
for the prevalence of diabetes which was much lower in GA+AA than GG individuals. These
data suggest that p.R4810K elevates the risk of CAD in those without diabetes; however, a
larger-scale study is needed to confirm this and to construct biomedically meaningful
hypotheses.
p.R4810K is the most common risk variant for MMD in East Asian countries [17], as well
as being associated with unilateral MMD and other intracranial arterial stenoses/occlusions.
[19,35] The homozygous RNF213 c.14429G>A variant was also previously shown to be associ-
ated with complications of MMD and pulmonary vasculopathy.[41] Its contribution to MMD
is high in East Asian countries, especially in Japan and South Korea (~80%).[17] In China, the
p.E4950D and p.A5021V variants as well as p.R4810K are frequently observed.[17,38] There-
fore, investigation of the associations among such variants and CAD would be worthwhile to
confirm the association of RNF213with CAD pathogenesis. The p.R4810K variant is not
found in Western countries,[17,39] suggesting that a search for ethnicity-specific rare variants
is important to fully clarify the genetic architecture of CAD.
RNF213 is located on chromosome 17q25.3, and encodes the 591 kDa (5207 amino acid)
protein mysterin, which possesses two functional domains: AAA+ ATPase and E3 ligase.
[17,42] The RNF213 protein assumes a hexameric structure that dynamically changes its for-
mation through ATP/ADP binding and hydrolysis cycles. It plays important roles in vascular
development, angiogenesis, and neuromuscular regulation.[17,42,43] In contrast, in mice, nei-
ther ablation nor the overexpression of Rnf213 p.R4757K (the ortholog of human RNF213 p.
R4810K) caused moyamoya phenotypes, indicating the existence of species differences in sen-
sitivity to vascular diseases that are unexplained.[44] In terms of molecular mechanisms,
Hitomi et al. showed that mutant RNF213 reduced angiogenesis of induced pluripotent stem
cell-derived vascular endothelial cells from p.R4810K carriers; [45] this was independently
confirmed by another group.[46] Such endothelial dysfunction may be related to CAD. Fur-
thermore, Hitomi et al. reported that p.R4810K induced a mitotic abnormality and genome
instability by the functional inhibition of the metaphase–anaphase spindle checkpoint protein
mitotic arrest deficiency 2.[47] More recently, it was reported that RNF213 targeted filamin A
and nuclear factor of activated T cells for proteasomal degradation, attenuating the non-
canonical Wnt/calcineurin pathway,[48] which plays a key role in angiogenesis and cardiac
development.[49] Further analyses will shed light on the molecular link between intracranial
and extracranial arterial diseases.
Susceptibility genes for CAD identified to date are mostly related to lipid metabolism, and
atherosclerosis is postulated to be a primary mechanism for narrowing of the coronary arter-
ies.[11] However, the pathological features of MMD are distinct from those of atherosclerosis
in that there is little macrophage infiltration or lipid deposition at the affected site.[50] Major
pathological findings of the intimal lesions in MMD include fibrous thickening with minimal
intracellular or extracellular lipid deposition, and minimal inflammatory cell infiltration with-
out significant disruption of the internal elastic lamina.[51–53] Ikeda et al. analyzed autopsy
specimens from patients with MMD and showed that the extracranial vessels, including the
coronary, pulmonary, renal, and pancreatic arteries, exhibited essentially the same intimal
lesions as the intracranial vessels.[54] The present study demonstrated an association of
RNF213with CAD, suggesting that CAD may be caused in part by a mechanism different
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from atherosclerosis. Although there remains a possibility that RNF213may indirectly affect
atherogenesis, CAD could represent a heterogeneous condition that is caused by various
mechanisms.
There are several limitations to this study. First, there were differences in the sex ratios and
age distribution between cases and controls in the primary study: the number of men was
higher in cases (72.4%) and lower (42.5%) among controls. A difference in age distribution
was also found in the replication study. Second, only small numbers of patients and controls
carried the p.R4810K variant (n = 50). Although we found that the prevalence of diabetes was
significantly lower in patients with the GA+AA genotypes than in those with the GG genotype,
we could not fully explain this. The difference implies that environmental risk factors may dif-
ferentially elevate susceptibility to CAD between those with the p.R4810K variant and those
without. Third, the p.R4810K genotypes in the replication study were imputed from genome-
wide genotyping data. Fourth, in the replication study, only a marginally significant associa-
tion of the p.R4810K variant with CAD was detected in the fully adjusted model. A larger
cohort study is therefore needed to confirm our observations.
Conclusions
In the present study, we found a significant association of the p.R4810K variant in RNF213
with CAD in the Japanese population. RNF213 is associated with various vascular phenotypes
including MMD, unilateral MMD, intracranial artery stenosis/occlusion, and CAD. Further
functional studies are needed to clarify how RNF213 affects the risk of vascular disease includ-
ing CAD and to illuminate the differences between RNF213-related vascular disorders and
atherosclerosis.
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